NCT02099084 - Short Bowel Syndrome and Teduglutide Versus Placebo | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Short Bowel Syndrome

Interventions

DRUG

Teduglutide

Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.

DRUG

Placebo

Participants will receive placebo matching study drug, administered subcutaneously.

Trial Locations (1)

Mayo Clinic in Rochester, Rochester